RxDoctor Payments Data

Jessica Ivey, MD

Internal Medicine · Knoxville, TNNPI 1124096136

Payments from drug & device makers

$5,641in general payments, 2019–2025

Across 404 payments — averaging $13.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$765
  • AstraZeneca$595
  • AbbVie$482
  • Novo Nordisk$474
  • Lilly USA, LLC$464
  • Amgen$379
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$5,616100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,641 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$223,960
Medicare patients
368
Services billed
6,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide123$120,441
EliquisApixaban91$108,164
JardianceEmpagliflozin65$72,247
TrulicityDulaglutide35$47,345
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$41,063
MounjaroTirzepatide29$31,401
LinzessLinaclotide32$29,081
XareltoRivaroxaban17$27,274
RybelsusSemaglutide17$24,882
Repatha SureclickEvolocumab23$18,907
JanuviaSitagliptin Phosphate16$18,626
VraylarCariprazine Hcl14$18,328
Tresiba Flextouch U-200Insulin Degludec16$18,258
Breo ElliptaFluticasone/Vilanterol18$15,855
GemtesaVibegron13$11,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$474$145,323140 claims
PfizerEliquis$765$108,16491 claims
Lilly USA, LLCTrulicity, Mounjaro$464$78,74564 claims
Boehringer IngelheimJardiance$54$72,24765 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$142$63,20391 claims
AbbVieLinzess, Vraylar, Synthroid$482$49,71296 claims
Johnson & JohnsonXarelto$114$27,27417 claims
MerckJanuvia, Janumet Xr$84$26,80729 claims
Sumitomo Pharma America, Inc.Gemtesa$56$11,89413 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$29$5,52712 claims
AstraZenecaSymbicort$595$3,49614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →